• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    6/21/24 9:00:00 AM ET
    $BIVI
    $MOB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Aerospace
    Industrials
    Get the next $BIVI alert in real time by email

    ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Mobilicom Ltd. (NASDAQ:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    BioVie: https://www.redchip.com/assets/access/bivi_access

    Mobilicom: https://www.redchip.com/assets/access/mob_access

    In an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs targeting unmet medical needs in neurodegeneration and liver disease. BioVie's lead asset, bezisterim (formerly NE3107), has demonstrated the ability to modulate TNFα production, leading to significant clinical improvements. Patients treated with bezisterim experienced reduced inflammation and insulin resistance, improved motor control and "morning on" symptoms in Parkinson's disease (PD), enhanced cognition and function, and better brain imaging scans in Alzheimer's disease (AD), as well as reduced DNA methylation levels. The Company's strategic priorities include launching a Phase 2b trial for Parkinson's in Fall 2024, initiating a Phase 3 trial for Alzheimer's in mid-2025 with a new once-daily formulation of bezisterim, continuing partnering discussions for bezisterim's geographic rights, and commencing an ascites Phase 3 trial upon identifying a suitable partner.

    Oren Elkayam, Founder and CEO of Mobilicom, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Mobilicom presents a strong investment opportunity with its comprehensive and proprietary technology suite. The company's products, including SkyHopper Datalinks, Ground Control Systems, Mobile Mesh Networking, the ICE Cybersecurity Suite, and CONTROLiT cloud management, form the core 'brain' of drones, providing control, guidance, and cybersecurity. Mobilicom's intellectual property, comprising trade secrets and 34 patent claims across two patent families, underscores its innovation leadership. With a global footprint, the company has secured over 50 customers in 18 countries and achieved 50 "design wins," indicating significant market penetration and long-term revenue potential. Mobilicom generated 43% revenue growth with 59% gross margin in 2023, and ended the year with a strong cash balance of $8.4 million. Combined with a narrowing monthly burn rate, this affords Mobilicom a long cash runway to implement its strategic plans, capture market share, and ramp revenues.

    About BioVie Inc.

    BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of ERK and NFκB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration ("FDA") Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com.

    About Mobilicom

    Mobilicom is a leading provider of cybersecure robust solutions for the rapidly growing defense and commercial drones and robotics market. Mobilicom's large portfolio of field-proven technologies includes cybersecurity, software, hardware, and professional services that power, connect, guide, and secure drones and robotics. Through deployments across the globe with over 50 customers, including the world's largest drone manufacturers, Mobilicom's end-to-end solutions are used in mission-critical functions.

    For investors, please use https://ir.mobilicom.com/
    For company, please use www.mobilicom.com

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

    Follow RedChip on Twitter: https://twitter.com/RedChip

    Follow RedChip on YouTube: https://www.youtube.com/@redchip

    Follow RedChip on Rumble: https://rumble.com/c/c-3068340

    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-407-644-4256
    info@redchip.com

    SOURCE: RedChip



    View the original press release on accesswire.com

    Get the next $BIVI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIVI
    $MOB

    CompanyDatePrice TargetRatingAnalyst
    BioVie Inc.
    $BIVI
    7/22/2022$7.00Overweight
    Cantor Fitzgerald
    BioVie Inc.
    $BIVI
    11/30/2021$50.00 → $27.00Buy
    B. Riley Securities
    More analyst ratings

    $BIVI
    $MOB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mobilicom to Participate in the Jefferies 2026 Defense Technology Virtual Summit on June 4, 2026, at 2:00pm EDT

    Palo Alto, California, June 02, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (NASDAQ:MOB, MOBBW), MOBBW) ("Mobilicom" or the "Company"), a provider of cybersecurity and robust solutions for drones and robotics, today announced that Oren Elkayam, Chief Executive Officer and Founder, will participate in a fireside chat at the Jefferies 2026 Defense Technology Virtual Summit. "We are honored to participate alongside many of the defense and technology sector's leading companies at this year's Jefferies Defense Technology Virtual Summit," said Oren Elkayam, CEO and Founder of Mobilicom. "The event provides an excellent opportunity to introduce new investors to Mobilicom's technology platform, o

    6/2/26 8:30:00 AM ET
    $MOB
    Aerospace
    Industrials

    Mobilicom Provides First Quarter 2026 Financial Highlights & Business Update

    Announces Progress in Second U.S. Department of War Program of Record Through Tier-1 Defense Partner Supporting the U.S. Army's LASSO Program $2.2 Million in New Orders from U.S. Tier-1 Customer for U.S. Department of War Program of Record Two New Design Wins with U.S. Tier-1 Drone Platforms and Expanding APAC and Middle East Engagements Drive Global Growth Granted FCC Trusted Drone Status for UAS Critical Components, Reinforcing Position in the Secure U.S. Defense Supply Chain Palo Alto, California, May 27, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (NASDAQ:MOB, MOBBW), MOBBW) ("Mobilicom" or the "Company"), a provider of cybersecurity and robust solutions for drones and robotics, t

    5/27/26 4:00:00 PM ET
    $MOB
    Aerospace
    Industrials

    Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2

    CARSON CITY, Nev., May 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on June 2, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), the Company's investigational oral drug candidate that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathwa

    5/27/26 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    $MOB
    SEC Filings

    View All

    SEC Form 6-K filed by Mobilicom Limited

    6-K - Mobilicom Ltd (0001898643) (Filer)

    5/27/26 4:01:29 PM ET
    $MOB
    Aerospace
    Industrials

    SEC Form 6-K filed by Mobilicom Limited

    6-K - Mobilicom Ltd (0001898643) (Filer)

    5/20/26 7:32:05 AM ET
    $MOB
    Aerospace
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Mobilicom Limited

    SCHEDULE 13G/A - Mobilicom Ltd (0001898643) (Subject)

    5/13/26 1:58:12 PM ET
    $MOB
    Aerospace
    Industrials

    $BIVI
    $MOB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Mobilicom Limited

    3 - Mobilicom Ltd (0001898643) (Issuer)

    3/18/26 8:52:21 AM ET
    $MOB
    Aerospace
    Industrials

    SEC Form 3 filed by Mobilicom Limited

    3 - Mobilicom Ltd (0001898643) (Issuer)

    3/18/26 8:51:21 AM ET
    $MOB
    Aerospace
    Industrials

    SEC Form 3 filed by Mobilicom Limited

    3 - Mobilicom Ltd (0001898643) (Issuer)

    3/18/26 8:50:18 AM ET
    $MOB
    Aerospace
    Industrials

    $BIVI
    $MOB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on BioVie Inc. with a new price target

    Cantor Fitzgerald initiated coverage of BioVie Inc. with a rating of Overweight and set a new price target of $7.00

    7/22/22 7:51:28 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities reiterated coverage on BioVie with a new price target

    B. Riley Securities reiterated coverage of BioVie with a rating of Buy and set a new price target of $27.00 from $50.00 previously

    11/30/21 8:23:48 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    $MOB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Do Cuong V bought 5,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    8/13/25 4:05:17 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Do Cuong V bought 10,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    3/6/24 5:12:41 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Do Cuong V bought $17,800 worth of shares (10,000 units at $1.78), increasing direct ownership by 17% to 68,759 units (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    12/1/23 6:26:32 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    $MOB
    Leadership Updates

    Live Leadership Updates

    View All

    Mobilicom Appoints Technology Executive Guy Givoni to its Board of Directors

    Givoni is a tech leader and senior executive with over two decades of experience building and scaling technology companies in the cybersecurity, drones, AI, B2B software and AgTech industries Palo Alto, California, June 05, 2025 (GLOBE NEWSWIRE) -- Mobilicom Limited (NASDAQ:MOB), a provider of cybersecurity and robust solutions for drones and robotics, today announced the appointment of Guy Givoni to its Board of Directors. Mr. Givoni previously served on Mobilicom's Advisory Board from 2017 through 2023. Mr. Givoni is a global business leader and senior executive with over 20 years of experience building and scaling technology companies in the cybersecurity, AI, UAV (uncrewed autonomo

    6/5/25 4:05:00 PM ET
    $MOB
    Aerospace
    Industrials

    BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

    The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

    5/5/25 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mobilicom Reports 2024 Year-End Financial Results: Record Revenues Up 45%

    Revenue momentum continues with robust gross margins, reduced operating expenses Major recent wins expected to drive growth include the addition of Mobilicom's systems to the U.S. Department of Defense's (DoD) Blue UAS Framework and its OS3 cybersecurity software platform for AI-Driven drones and robotics Strong cash position of $8.6 million with low average monthly net burn rate of $267K provides a long cash runway to support growth PALO ALTO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB), a provider of cybersecurity and robust solutions for drones and robotics, today announced financial results for the twelve months ended December 31, 2024, as well as rece

    3/27/25 4:15:24 PM ET
    $MOB
    Aerospace
    Industrials

    $BIVI
    $MOB
    Financials

    Live finance-specific insights

    View All

    Mobilicom Provides First Quarter 2026 Financial Highlights & Business Update

    Announces Progress in Second U.S. Department of War Program of Record Through Tier-1 Defense Partner Supporting the U.S. Army's LASSO Program $2.2 Million in New Orders from U.S. Tier-1 Customer for U.S. Department of War Program of Record Two New Design Wins with U.S. Tier-1 Drone Platforms and Expanding APAC and Middle East Engagements Drive Global Growth Granted FCC Trusted Drone Status for UAS Critical Components, Reinforcing Position in the Secure U.S. Defense Supply Chain Palo Alto, California, May 27, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (NASDAQ:MOB, MOBBW), MOBBW) ("Mobilicom" or the "Company"), a provider of cybersecurity and robust solutions for drones and robotics, t

    5/27/26 4:00:00 PM ET
    $MOB
    Aerospace
    Industrials

    BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

    -Topline Data Release Targeted Late Summer 2026- CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced full enrollment of the Company's ADDRESS-LC Phase 2 trial evaluating its drug candidate bezisterim for the treatment of neurological symptoms of Long COVID. The Phase 2 study is fully funded by a grant from the U.S. Department of War (DoW, formerly the U.S. Department of Defense). An estimated 15 million U.S. adults reported having long COVID between 2022 and 2023, with 3.8 million experiencing significant lim

    5/26/26 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mobilicom to Report First Quarter 2026 Financial and Operating Highlights on Wednesday, May 27, 2026

    Palo Alto, California, May 20, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (NASDAQ:MOB, MOBBW), MOBBW) ("Mobilicom" or the "Company"), a provider of cybersecurity and robust solutions for drones and robotics, today announced that it will issue a press release with financial and operational highlights for the three months ended March 31, 2026 after the Nasdaq Stock Market closes on Wednesday, May 27, 2026. The Company's management will also discuss these highlights and other recent developments, followed by a Q&A session, on a conference call and webcast at 4:30 p.m. EDT the same day. Investors are invited to email questions to the Company in advance to: ir@mobilicom.com. Conference call

    5/20/26 4:00:00 PM ET
    $MOB
    Aerospace
    Industrials

    $BIVI
    $MOB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mobilicom Limited

    SC 13G/A - Mobilicom Ltd (0001898643) (Subject)

    11/13/24 5:28:41 PM ET
    $MOB
    Aerospace
    Industrials

    SEC Form SC 13G filed by BioVie Inc.

    SC 13G - BIOVIE INC. (0001580149) (Subject)

    10/25/24 4:01:25 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BioVie Inc.

    SC 13D/A - BIOVIE INC. (0001580149) (Subject)

    6/25/24 7:47:33 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care